FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washing

-to D.C. 20E40	-
gton, D.C. 20549	OMB APPROVA
	UIVID APPROVA

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* GOLD DANIEL P PHD					2. Issuer Name and Ticker or Trading Symbol MEI Pharma, Inc. [MEIP]										k all applical		reporting Person(s) to Issuer le) 10% Owner		
C/O MEI PHARMA, INC.					3. Date of Earliest Transaction (Month/Day/Year) 11/16/2012									X	Officer (g below)		Other (specify below)		ecify
11975 EL CAMINO REAL, SUITE 101					4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable					
(Street) SAN DII	EGO C	A	92130		4. II Americani, Pate of Original Fried (Month/PDay/Teal)								Line)						
(City)	(5	State)	(Zip)																
		T	able I - Non-D	erivat	tive S	ecu	rities A	cqu	uired, C	Dispo	osed	of, or Ben	efic	ially (Owned				
1. Title of Security (Instr. 3) 2. Transa Date (Month/D				te	Day/Year) if		2A. Deemed Execution Date, if any (Month/Day/Year		Code (Instr.		4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4				y	Form:	Direct Indirect Btr. 4)	7. Nature of Indirect Beneficial Ownership	
						Code			v	Amoun	nt (A) or (D)		ice	Transaction(s) (Instr. 3 and 4)				nstr. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Exp	6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount Securities Underlyin Derivative Security (Instr. 3 and 4)				9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	e s lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Dat Exe	e ercisable	Expii Date	ration	Title	Amo or Num of S			(Instr. 4)			
Options to purchase shares of common stock	\$1.42	11/16/2012		A			300,000		(1)	([2)	Common Stock, par value \$0.00000002 per share	300),000	\$0	720,39	90	D	

Explanation of Responses:

1. 200,000 of the options vested on November 16, 2012; the remaining 100,000 of Dr. Gold's options will vest upon the closing of the Securities Purchase Agreement dated November 4, 2012, by and among MEI Pharma, Inc., Vivo Ventures Fund VII, L.P., Vivo Ventures VII Affiliates Fund, L.P., New Leaf Ventures II, L.P., and certain other accredited investors identified in Exhibit A thereto, which was filed as Exhibit 10.1 to a Current Report on Form 8-K by MEI Pharma, Inc. on November 5, 2012.

2. The options expire November 15, 2017.

/s/ Daniel P. Gold

** Signature of Reporting Person

11/20/2012

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.